Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases

Pfizer has entered into an exclusive licensing agreement with Starna Therapeutics, a biotechnology company developing RNA medicines designed to enable in vivo therapeutics.
Starna will receive an upfront payment of $330 million, and is eligible to receive up to $2.3 billion in milestone payments associated with certain development and commercial milestones, plus royalties on net sales of approved products.
Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialise three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programmes that are focused on treating autoimmune diseases.
Pfizer will lead clinical development outside Greater China and plans to manufacture the finished drug product for the initial clinical trials using its facilities in theUS .
Pfizer will have sole and exclusive control over commercialisation outside of Greater China for all products. Pfizer holds options to expand its territory to include Greater China.
Pfizer also receives rights to use Starna’s proprietary in vivo CAR-T technology in inflammation and immunology, and in oncology, as well as options to exclusively license compounds created under a separate research collaboration and an option to expand the territory to include exclusive rights to develop and commercialise each exclusively licensed compound and product in Greater China.
The post Pfizer, Starna Therapeutics enter exclusive licensing agreement for autoimmune diseases appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
